Sanofi SA (NASDAQ:SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route.An acquisition of Biomarin would be another step in Sanofi's plan to get out of heart and diabetes research and into cancer, immune diseases and uncommon blood disorders, according to an article in BioPharma Dive.